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Background
Severe acute respiratory failure in adults causes high mortality despite improvements in ventilation techniques and 
other treatments (e.g., steroids, prone positioning, bronchoscopy, and inhaled nitric oxide).
Methods
Objective: We aimed to delineate the safety, clinical effi   cacy, and cost-eff  ectiveness of extracorporeal membrane 
oxygenation (ECMO) compared with conventional ventilation support.
Design: Randomized controlled trial.
Setting: UK-based multicenter trial from July 2001 to August 2006.
Subjects: 180 adults aged 18–65 years with severe (Murray score >3.0 or pH <7.20) but potentially reversible 
respiratory failure. Exclusion criteria were: high pressure (>30 cm H2O of peak inspiratory pressure) or high FiO2 (>0.8) 
ventilation for more than 7 days; intracranial bleeding; any other contraindication to limited heparinization; or any 
contraindication to continuation of active treatment.
Intervention: Subjects were randomly assigned in a 1:1 ratio to receive continued conventional management or 
referral to consideration for treatment by ECMO.
Outcomes: The primary outcome was death or severe disability at 6 months after randomization or before discharge 
from hospital. Primary analysis was by intention to treat. Only researchers who did the 6-month follow-up were 
masked to treatment assignment. Data about resource use and economic outcomes (quality-adjusted life-years) were 
collected. Studies of the key cost generating events were undertaken, and we did analyses of cost-utility at 6 months 
after randomization and modeled lifetime cost-utility.
Results
766 patients were screened; 180 were enrolled and randomly allocated to consideration for treatment by ECMO (n=90 
patients) or to receive conventional management (n=90). 68 (75%) patients actually received ECMO; 63% (57/90) of 
patients allocated to consideration for treatment by ECMO survived to 6 months without disability compared with 
47% (41/87) of those allocated to conventional management (relative risk 0.69; 95% CI 0.05-0.97, p=0.03). Referral to 
consideration for treatment by ECMO led to a gain of 0.03 quality-adjusted life-years (QALYs) at 6-month follow-up. A 
lifetime model predicted the cost per QALY of ECMO to be £19 252 (95% CI 7622-59 200) at a discount rate of 3.5%.
Conclusions
We recommend transferring of adult patients with severe but potentially reversible respiratory failure, whose Murray 
score exceeds 3.0 or who have a pH of less than 7.20 on optimum conventional management, to a centre with an 
ECMO-based management protocol to signifi  cantly improve survival without severe disability. This strategy is also 
likely to be cost-eff  ective in settings with similar services to those in the UK. (ISRCTN47279827)
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Th   e use of ECMO for the treatment of acute respiratory 
failure in adults has been debated since the mid-1970s. 
Prior to the publication of the Conventional ventilation 
or ECMO for Severe Adult Respiratory failure (CESAR) 
trial results, there were two negative randomized con-
trolled trials [2,3] in contradistinction to a number of 
positive institutional experiences [4-7]. Th   e relevancy of 
these randomized trials to modern ECMO has been 
questioned due to issues of case selection, ventilation 
strategies, extracorporeal circuit design, and disease 
management that were completely diﬀ  erent from modern 
protocols.
CESAR is the ﬁ  rst contemporary randomized controlled 
trial of ECMO referral for respiratory failure in adults 
compared to conventional supportive critical care. 
Importantly, the intervention in CESAR was referral to 
an ECMO center not treatment with ECMO. In fact, only 
75% of ECMO-referred patients actually received ECMO. 
Despite this limited application, the two major eﬀ  ects of 
the intervention were impressive. First, management of 
adults with severe respiratory failure at a center that has 
ECMO capability resulted in increased 6-month survival 
without severe disability compared to conventional 
management. Second, referral to a center that has ECMO 
capability was cost-eﬀ  ective from the perspective of the 
UK National Health Service. Th   e absolute risk reduction 
for the primary outcome was 16%, which translates into a 
number-needed-to-treat of 6.2 patients. Put another way, 
the intervention will result in one additional life saved for 
every 6.2 in whom it is attempted, compared to con-
ventional management.
Strengths of the trial were an early assignment to 
treatment groups, intention-to-treat analysis, incorpora-
tion of transport risk into trial design, and a robust 
economic analysis. Th   e forethought of their design allows 
the ﬁ  ndings to be considered pragmatically and recon-
ciles some unanswered questions regarding ECMO use. 
Importantly, the study shows that ECMO referral is 
beneﬁ  cial – rather than the narrower question of only 
ECMO use. Th   is distinction allows a broader take on the 
study ﬁ  ndings. Th  e overwhelming majority of hospitals 
responsible for the management of adults with severe 
respiratory failure do not have ECMO capabilities, 
though they are responsible for the decision to refer 
patients to a center that does.
Despite the strengths of this study, there are several 
limitations that challenge both the generalizability and 
validity of the ﬁ  ndings. As the management of patients 
randomized to ECMO-consideration was performed at 
an expert high case volume center, it bears questioning 
whether the results would be similar in smaller or less 
experienced centers [8]. Furthermore, the argument can 
be made that the ﬁ   ndings are speciﬁ   c to the United 
Kingdom’s health care system and not generalizable to 
other health care networks. In fact, the translation of 
currency into US dollars should really only be interpreted 
for scale, rather than as a reﬂ  ection of cost-eﬀ  ectiveness 
from a US perspective. Th   ree patients in the conventional 
group who were known to be alive at 6 months but who 
asked to be withdrawn from the study were excluded 
from the calculation of the primary endpoint due to 
missing information about severe disability. As the 
authors point out, assuming that these three patients had 
all been severely disabled, or had not been severely 
disabled, the relative risk of the primary outcome would 
be 0.67 (95% CI 0.48–0.94, p=0.017), and 0.72 (0.51–1.01, 
p=0.051), respectively. In the latter comparison, the 
primary endpoint narrowly misses the threshold for 
signiﬁ  cance.
A more concerning aspect of the study was the lack of a 
management protocol for patients randomized to con-
ven  tional treatment, leaving the reader to wonder if the 
ECMO referral group was compared to an appropriate 
standard of care. Th  e authors indicate there was a 
diﬀ  erence of 23% between treatment groups with respect 
to the use of a lung protective ventilation strategy at any 
time. Could lower adherence to this strategy in the con-
ven  tional management group account for the mortality 
diﬀ  erence observed or was it universally attempted but 
not possible in the sickest patients due to the severity of 
their underlying disease? We wonder.
Th   e CESAR trial clearly informs our understanding of 
the role of ECMO referral in a modern health care 
network, but will likely not represent the ﬁ  nal referendum 
on this technology. Further study is needed to show that 
the results of CESAR are not merely speciﬁ  c to the single 
ECMO center in the study or to the United Kingdom, but 
that they apply to all adults with severe respiratory 
failure. Th  e  cost-eﬀ  ectiveness analysis is encouraging, but 
modeling in other health care environments would be 
needed prior to wholesale adoption. Ultimately, ECMO 
will likely remain a luxury commodity without high-
volume use, and as such will continue to have a place in 
the management of severe respiratory failure at referral 
centers – independent of cost-eﬀ   ectiveness. Will new 
challenges such as inﬂ  uenza H1N1 force us to reconsider 
the economic burden of ECMO [9]? If so, the optimal 
positioning of centers with this capability will need to be 
determined as will protocols for initiating referrals and 
transfers. Time and circumstance will tell.
Recommendation
Referral of adult patients with severe respiratory failure 
to an ECMO-capable facility results in improved 
6-month survival without disability and is cost-eﬀ  ective 
from the standpoint of the UK National Health Service. 
Replication of the CESAR ﬁ  ndings will establish whether 
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oﬀ  ers a preferred management strategy for patients with 
severe respiratory failure.
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